Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/17/2026, 12:00:00 AM
HSBC downgraded the stock to "Reduce" from "Hold," citing concerns that the obesity drug market is overvalued. The stock fell approximately 6% on the day of the announcement.
Korean Translation
HSBC가 비만 치료제 시장이 고평가되었다는 우려를 제기하며 투자의견을 '보유'에서 '축소'로 하향 조정함. 발표 당일 주가는 약 6% 하락함.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Q1 2026 earnings release is scheduled.
4/21/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
New target action date for the FDA's decision on oral obesity drug orforglipron, following an extension of the review period announced on January 15, 2026, scheduled; a price impact of at least 1% is expected.
4/10/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Other
The company is scheduled to present five studies at the 2026 USCAP Annual Meeting from 2026-03-21 to 2026-03-26 scheduled.
3/21/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial for its investigational drug retatrutide, which showed significant reductions in A1C and body weight for adults with type 2 diabetes; a price impact of over 10% is estimated.
3/19/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Other
Appeals court ruling on whistleblower lawsuit regarding 340B program overcharging allegations scheduled for March 18, 2026; moderate impact expected from potential legal liabilities, scheduled.
3/18/2026, 12:00:00 AM